Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC NIT6ZplIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2m4OolvcGmkaYTzJJRp\SCYRVfGMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCxZjDIWXZGS3N? NXrR[2pLOTh4MkCzPFI>
HUVEC NWPLZWU4U2mwYYPlJIF{e2G7 NVHSeG9HcW6qaXLpeJMhXkWJRj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDWSWdHWi1{IHnuJGhWXkWFIHPlcIx{KHerdHigZY4hUUN3MDDv[kDjkLx6IH7N NEPPTmUyQDZ{MEO4Ni=>
MM MWnLbY5ie2ViYYPzZZk> NXrJZVh7cW6qaXLpeJMhXkWJRj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDmcJQy MWKxO|E3PDN|Mh?=
MM.1S M37CPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NETRXoMyOCEQvHevcWw> NV7DOGl4cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= Ml35NVcyPjR|M{K=
MM.1R MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmL5NVAh|rypL33M MnzMbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? M{DIZ|E4OTZ2M{Oy
RPMI MkDoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NU\yR5pPOTBizsznM41N M17MPIlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq NFi4dGwyPzF4NEOzNi=>
Dox40 NUTpR21DT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3XuOFExKM7:Zz;tUC=> MXrpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MkjGNVcyPjR|M{K=
INA-6 M1fIfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYCyNoYzOTBizsznM41N NWHGOI9ZcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= Mn7jNVcyPjR|M{K=
OPM2 NFHV[pFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUn2TlFJOTBizsznM41N M3v4bolvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq Ml:0NVcyPjR|M{K=
U266 M1HTSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWTGb4lyOTBizsznM41N M4DmOYlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq Moe4NVcyPjR|M{K=
MM.1S NEjiWVdkgXSxdH;4bYNqfHliYYPzZZk> MYGyNEDPxGdxbVy= M1zMTolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MmG4NVcyPjR|M{K=
MM.1R NX;OWZZp[3m2b4TvfIlkcXS7IHHzd4F6 M1T1PVIxKM7:Zz;tUC=> NI[4cIxqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MUixO|E3PDN|Mh?=
RPMI M1\NW4N6fG:2b4jpZ4l1gSCjc4PhfS=> NHf4[5YzOCEQvHevcWw> M2HPXIlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NI[xS4MyPzF4NEOzNi=>
Dox40 MlzpZ5l1d3SxeHnjbZR6KGG|c3H5 NFHL[JYzOCEQvHevcWw> NHLpV2VqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs NFfwV5gyPzF4NEOzNi=>
INA-6 MnHHZ5l1d3SxeHnjbZR6KGG|c3H5 MX:yNEDPxGdxbVy= MUDpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NX;qeVdGOTdzNkSzN|I>
OPM2 NEPCbGlkgXSxdH;4bYNqfHliYYPzZZk> NWfCPZFnOjBizsznM41N NGPRUpJqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs M1XvZ|E4OTZ2M{Oy
U266 NVPyS5BF[3m2b4TvfIlkcXS7IHHzd4F6 MXqyNEDPxGdxbVy= NWG3TYMycW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> M3jscVE4OTZ2M{Oy
MM.1S NV\2S4tkTnWwY4Tpc44h[XO|YYm= MXvzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? NHfI[24yPzF4NEOzNi=>
MM.1R NF;oNHFHfW6ldHnvckBie3OjeR?= M4nG[ZN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= MlH6NVcyPjR|M{K=
Dox40 NGTj[JpHfW6ldHnvckBie3OjeR?= MoXPd5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w M2rubVE4OTZ2M{Oy
OPM2 NX;QW3ZzTnWwY4Tpc44h[XO|YYm= MVXzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? MWmxO|E3PDN|Mh?=
HBMEC NFzQSlZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4\wep4yOCEQvF2= NUjTfm5rTE2VTx?= MX;JR|UxRTFizszN MmX0NlExQDF4NU[=
HBMEC MnTjSpVv[3Srb36gZZN{[Xl? MX\+NUDPxE1? NFrOVXRFVVOR MYnhZpJw\2G2ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCYRVfGVlIhf2m2aDDkbZNzfXC2aX;uJI9nKGSxd37zeJJm[W1iUFzD{tMy MlP0NlExQDF4NU[=
HBMEC NIL1PVdHfW6ldHnvckBie3OjeR?= NYPhNoM6hjFizszN NF7nVHJFVVOR NX75e5V3\Gm|coXweJMhfGinIGLhd{1T[WZvRWLLJJBifGi5YYmgeIhzd3WpaDDk[YNz\WG|ZXSgdIhwe3Cqb4L5cIF1\WRiTVXLNU8zKGGwZDDFVmsyNzJ? Mn\pNlExQDF4NU[=
HBMEC NWTMXGtlTnWwY4Tpc44h[XO|YYm= MUf+NlAh|ryP NHi1XZpFVVOR MWrkbZNzfXC2czC1NEUhd2ZidIXi[UBnd3KvYYTpc44h[XRiMTFOwG0> MWGyNVA5OTZ3Nh?=
MDA-MB-231 NFvWT3lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4LocZ4yOCEQvF2= NX7vXIxUTE2VTx?= MYLJR|UxRTVizszN NE\wfoMzOTB6MU[1Oi=>
MDA-MB-231 MYLGeY5kfGmxbjDhd5NigQ>? MYiwMlUh|ryP NHS2UGVFVVOR NHL6[mlqdmirYnn0d{B1cGViRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6 M3zmNVIyODhzNkW2
MDA-MB-231 MnLtSpVv[3Srb36gZZN{[Xl? Mnf6OUDPxE1? NF7Xb4VFVVOR NETH[HZqdmS3Y3XzJIEh[2WubD3jfYNt\SCjcoLld5Q> NYPvTphSOjFyOEG2OVY>
J82 NWTIXnJT[3m2b4TvfIlkcXS7IHHzd4F6 MlvGglExKM7:TR?= M3\I[WROW09? MVfJR|UxRTJ2LkW3JO69VQ>? M1OwZVIyPTJ7OUCw
T24 NYDudm5I[3m2b4TvfIlkcXS7IHHzd4F6 M2PhfJ4yOCEQvF2= MWrEUXNQ NX\zOGlvUUN3ME21Nk41PSEQvF2= NGLYUWczOTV{OUmwNC=>
HT1376 NWrwPHls[3m2b4TvfIlkcXS7IHHzd4F6 Mn62glExKM7:TR?= Mn;2SG1UVw>? NWPMbJUzUUN3ME2yPE4zOSEQvF2= Moj2NlE2Ojl7MEC=
RT4 NHrBeW1kgXSxdH;4bYNqfHliYYPzZZk> NHS5W|Z,OTBizszN NH3oO|JFVVOR M2\xOmlEPTB;NT6xOEDPxE1? NYD5V5ZGOjF3Mkm5NFA>
CRL1749 MoLoZ5l1d3SxeHnjbZR6KGG|c3H5 MX3+NVAh|ryP M3PMRmROW09? NEDJPWRKSzVyPUKyMlY6KM7:TR?= Mnu5NlE2Ojl7MEC=
HTB9 M4PoT4N6fG:2b4jpZ4l1gSCjc4PhfS=> MmTvglExKM7:TR?= NWHWSm9ETE2VTx?= NFzBSldKSzVyPUGxMlg1KM7:TR?= MVyyNVUzQTlyMB?=
Sup NWn0TYdt[3m2b4TvfIlkcXS7IHHzd4F6 M2flTp4yOCEQvF2= NETBSmJFVVOR MmX5TWM2OD13Mz6zNkDPxE1? NInS[2YzOTV{OUmwNC=>
HTB3 NWf3cm04[3m2b4TvfIlkcXS7IHHzd4F6 NXjUXpVQhjFyIN88US=> NFvybm5FVVOR MnP1TWM2OD1zND6xOkDPxE1? MUWyNVUzQTlyMB?=
CEC NUWwZ4c3TnWwY4Tpc44h[XO|YYm= M13pXJ4yOCEQvHevcWw> M3O1XWROW09? M3GwVYRwf25vcnXneYxifGW|IG\FS2YhdGW4ZXzz MonnNlE3OjB6MkK=
RPE M3r5R2Z2dmO2aX;uJIF{e2G7 NG\ac3N,OTBizsznM41N Mom0SG1UVw>? M{fuRoRwf25vcnXneYxifGW|IG\FS2YhdGW4ZXzz M1vqVlIyPjJyOEKy
CEC M1Hx[mZ2dmO2aX;uJIF{e2G7 M4PJVZ42KM7:Zz;tUC=> MV\EUXNQ NXm3TZkz[myxY3vzJIVv\G:2aHXsbYFtKGOnbHygcYloemG2aX;u NUjZcZpEOjF4MkC4NlI>
5637 NXj6T414T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NV;QRlFkTE2VTx?= NEHkWYxKSzVyPUG1MlDjiIoQvF2= MnrXNlM5QDd4MEW=
J82 NFfpOFdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkTLSG1UVw>? M4nCfmlEPTB;MUiuOQKBkc7:TR?= NFW5V44zOzh6N{[wOS=>
5637 NGrETopCfXSxcHjh[5kh[XO|YYm= NUL5fnp4OjBizszN NWXzO|duTE2VTx?= NVvaV2NFfHKrZ3fldpMhfGinIHH1eI9xcGGpaXOgdJJw[2W|cx?= NFvNW|AzOzh6N{[wOS=>
J82 NVPDcVFCSXW2b4DoZYd6KGG|c3H5 NXSwc2dxOjBizszN M1zQc2ROW09? MWD0dolo\2W{czD0bIUh[XW2b4DoZYdq[yCycn;j[ZN{ NE\hWG4zOzh6N{[wOS=>
5637 M1rSXWZ2dmO2aX;uJIF{e2G7 MXyyNEDPxE1? NXjlNIxvTE2VTx?= NHHxV49qdmS3Y3XzJIx6e2:|b33hcE1l\XCnbnTlcpQhdmWlcn;zbZM> NUDrSoRiOjN6OEe2NFU>
J82 Mm\XSpVv[3Srb36gZZN{[Xl? NXLDSnpZOjBizszN NInUSpBFVVOR MVrpcoR2[2W|IHz5d49{d22jbD3k[ZBmdmSnboSgcoVkem:|aYO= MYqyN|g5PzZyNR?=
5637 MYPGeY5kfGmxbjDhd5NigQ>? NUfSS5VqOjBizszN M2fBdmROW09? MYfpcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7 MlXxNlM5QDd4MEW=
J82 MmrMSpVv[3Srb36gZZN{[Xl? NUT1fmN{OjBizszN NFvXUGZFVVOR MX\pcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7 MnvhNlM5QDd4MEW=
KATO-II NXjkNIFQT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXXTUXd{PSEQvF2= MYnEUXNQ MnPNZoxw[2u|IIDyc4xq\mW{YYTpc44> M3;jSlI2OjR7NUW3
OCUM-2M MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVjnT5FzPSEQvF2= M4WwPWROW09? MXjicI9kc3NicILvcIln\XKjdHnvci=> NHrSb|MzPTJ2OUW1Oy=>
SNU-16 MoH4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlPtOUDPxE1? NYfDeG1CTE2VTx?= MXTicI9kc3NicILvcIln\XKjdHnvci=> MXSyOVI1QTV3Nx?=
HSC-39 M13QXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MV[1JO69VQ>? MVrEUXNQ NF[yfIxjdG:la4OgdJJwdGmoZYLheIlwdg>? MYGyOVI1QTV3Nx?=
KATO-II MkLMZ5l1d3SxeHnjbZR6KGG|c3H5 MoTGglExKM7:TR?= NV7PfZNNTE2VTx?= MVjJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? NEGxTpAzPTJ2OUW1Oy=>
OCUM-2M NWX4Z2pq[3m2b4TvfIlkcXS7IHHzd4F6 NIDNe3N,OTBizszN NV\mRoQ3TE2VTx?= NVTYPWp6UUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= NYnsWWNJOjV{NEm1OVc>
SNU-16 Mne3Z5l1d3SxeHnjbZR6KGG|c3H5 M{XjOp4yOCEQvF2= Mn:zSG1UVw>? MVXJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? MkG3NlUzPDl3NUe=
HSC-39 NXG3eY82[3m2b4TvfIlkcXS7IHHzd4F6 MVz+NVAh|ryP MlW5SG1UVw>? NFXBfIxKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= MX6yOVI1QTV3Nx?=
NIH 3T3 NHftfmxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlLwglExKM7:TR?= MU\EUXNQ NXO0TVdpcW6qaXLpeJMh[2WubDDndo94fGhiYX7kJINwdG:weTDmc5Ju[XSrb36= NYnlNGdpOjV{NEm1OVc>
KATO-III MkTjSpVv[3Srb36gZZN{[Xl? MYexJO69VQ>? NFLabVFFVVOR M3rRbolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NEHZUpozPTJ2OUW1Oy=>
OCUM-2M MWXGeY5kfGmxbjDhd5NigQ>? NUDpdYV7OSEQvF2= M1nn[GROW09? MnXabY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= NXjvbVRFOjV{NEm1OVc>
KATO-III NFToblZCeG:ydH;zbZMh[XO|YYm= MVKxJO69VQ>? M1TnSWROW09? MV;pcoR2[2W|IHHwc5B1d3Orcx?= MoLMNlUzPDl3NUe=
OCUM-2M M{DLcGFxd3C2b4Ppd{Bie3OjeR?= NVSxWI1XOSEQvF2= MkT6SG1UVw>? MVrpcoR2[2W|IHHwc5B1d3Orcx?= MUeyOVI1QTV3Nx?=
KATO-III MnK0SpVv[3Srb36gZZN{[Xl? MUGxJO69VQ>? MojMSG1UVw>? NUWzeGlycW6qaXLpeJMhTkeIUkKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\yCvb3zlZ5Vt\XN? NITLSWQzPTJ2OUW1Oy=>

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID